West on Lung Cancer

• Which Patients With CNS Metastases Can Avoid Radiation?   Thoracic oncologists Drs Jack West and Hossein Borghaei talk about the CNS activity of new lung cancer agents and whether it means some patients can forgo radiotherapy.
  Medscape Oncology, May 2018
• Dealing With Data Overload in Oncology   From pharmaceutical press releases to highly motivated online patient groups, oncologists are on the receiving end of a firehose of information. Here are some solutions.
  Medscape Oncology, May 2018
• Time to 'Rethink' Immunotherapy for Molecularly Driven NSCLC   Drs West and Borghaei discuss IMpower150 and why clinicians should reconsider using immunotherapy as a last line of defense in molecularly driven NSCLC.
  Medscape Oncology, May 2018
• Trial 'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer   Thoracic oncologists Drs Jack West and Hossein Borghaei discuss critical questions in the treatment of low-expressing or PD-L1-negative non-small cell lung cancer patients.
  Medscape Oncology, May 2018
• KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC   While KEYNOTE-189 answered many questions about immuno-oncology for NSCLC, Drs West and Borghaei look forward to results of KEYNOTE-042 for even more answers.
  Medscape Oncology, May 2018
• PFS Is a Shortcut, Not a Destination Oncologists need to remember that PFS is a surrogate for the most important endpoint--how long our patients live, argues H. Jack West, MD.
  Medscape Oncology, May 2018
• Is This New Immunotherapy Biomarker Really 'Ready for Primetime'?   Drs West and Borghaei discuss the current state of tumor mutational burden as a potential biomarker for lung cancer.
  Medscape Oncology, May 2018
• Interpreting KEYNOTE-189 and CheckMate-227 for Clinical Practice Thoracic oncologist H. Jack West, MD, takes a close look at the clinical implications of two major lung cancer clinical trials presented at AACR.
  Medscape Oncology, April 2018
• 'Reinventing Healthcare' Without the People Who Care for Patients In this commentary, Dr Jack West points out that a unifying theme of the many conferences and companies purporting to disrupt healthcare is that they don't include actual physicians in their planning.
  Medscape Oncology, March 2018
• It's Time to Renew Our Vows With Evidence-Based Medicine Evidence-based medicine is being undermined on many sides, argues Dr Jack West. And the medical community is complicit.
  Medscape Oncology, February 2018
• Top 5 Practice-Changing Developments in Lung Cancer in 2017 Last year was a big one for lung cancer therapy developments. Here are five of the most clinically relevant, with a brief commentary by lung cancer expert H. Jack West, MD.
  Medscape Oncology, January 2018
• 'Stepping Back From the Hype': A Critical Look at NGS In the absence of clinical data to guide treatment decisions, oncologists should question whether identifying more tumor targets is inherently better, argues Dr Jack West.
  Medscape Oncology, December 2017
• Tumor Mutational Burden as a Immunotherapy Predictive Biomarker Tumor mutational burden, a measurement of the overall number of genomic alterations seen in a cancer, may be a potentially helpful marker to predict response to immunotherapy.
  Medscape Oncology, November 2017
• ESMO's Practice-Changing Lung Cancer Data: Three Experts Discuss   At ESMO 2017, Jack West discussed new, potentially practice-changing immunotherapy research with Hossein Borghaei and Sanjay Popat.
  Medscape Oncology, November 2017
• Immunotherapy for Lung Cancers: First-Line and Beyond   Drs West, Garon, and Borghaei discuss immunotherapy for selected lung cancers and the potential roles and pitfalls of combination immunotherapy.
  Medscape Oncology, November 2017
• Jack West, MD: Top Five Lung Cancer Abstracts at ESMO 2017 Lung cancer specialist Dr Jack West previews the most important lung cancer studies being presented at the ESMO 2017 Congress in Madrid.
  Medscape Oncology, September 2017
• Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep? Though they have received a lot of hype as the heir apparent in lung cancer therapy, the early signals on combining immunotherapies are not reassuring, cautions Dr Jack West.
  Medscape Oncology, August 2017
• Adjuvant TKI Therapy for Early-Stage EGFR Mutation-Positive NSCLC Is disease-free survival an appropriate endpoint in studies where the goal is cure?
  Medscape Oncology, July 2017
• Expert Panel: Should Genomic Testing Be Broadly Used in Cancer?   Experts respond to a Medscape survey of oncologists on the limits of genomic testing in cancer care.
  Medscape Oncology, May 2017
• New Standard of Care for EGFR Mutation-Positive Advanced NSCLC Dr Jack West talks about the new role of osimertinib for NSCLC patients with EGFR mutation-positive acquired resistance.
  Medscape Oncology, May 2017